Fertil Steril. 2010 Aug;94(3):1138-40. doi: 10.1016/j.fertnstert.2009.11.030. Epub 2010 Jan 8.

The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.

Source

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California, USA. jmerse@med.unc.edu

Abstract

Compared with placebo, alendronate treatment resulted in a significant protection against bone loss in healthy perimenopausal women. This protection occurred at both the spine and the hip and was evident after 6 months of therapy.

PMID:: 20056199; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Osteoporosis - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. [Ann Intern Med. 2002]
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, et al. Ann Intern Med. 2002 Dec 3; 137(11):875-83.
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. [J Clin Endocrinol Metab. 2001]
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group. J Clin Endocrinol Metab. 2001 Mar; 86(3):1116-25.
Denosumab in postmenopausal women with low bone mineral density. [N Engl J Med. 2006]
Denosumab in postmenopausal women with low bone mineral density.
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, et al. N Engl J Med. 2006 Feb 23; 354(8):821-31.
Review Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. [Curr Med Res Opin. 2006]
Review Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J, Takeda T, Sato Y. Curr Med Res Opin. 2006 May; 22(5):919-28.
Review Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. [Clin Interv Aging. 2008]
Review Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature.
Iwamoto J, Sato Y, Takeda T, Matsumoto H. Clin Interv Aging. 2008; 3(3):483-9.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

The role of alendronate in mitigating perimenopausal bone loss: a double-blind r...
The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.
Fertil Steril. 2010 Aug ;94(3):1138-40. doi: 10.1016/j.fertnstert.2009.11.030. Epub 2010 Jan 8 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information